Gordon Murdo

SEC source: 0000318154-26-000085 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,222

F1 · balance_after: These shares include 386 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000079 · form4.xml · nonDerivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,837

F2 · balance_after: These shares include 458 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000079 · form4.xml · derivative · entry 3

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,752

Underlying: Common Stock · 23,752 shares

Expires 2036-05-05

F3 · derivative.exercise_date: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.

SEC source: 0000318154-26-000079 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,339

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

SEC source: 0000318154-26-000061 · form4.xml · nonDerivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,699

F1 · balance_after: These shares include 488 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000061 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,462

SEC source: 0000318154-26-000026 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,292

F1 · balance_after: These shares include 825 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-26-000015 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,807

F1 · balance_after: These shares include 740 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0000318154-25-000081 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,923

F1 · price: The price reported is an average price. The prices ranged from $336.7301 to $337.0500 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include 647 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-013780 · form4.xml · derivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,334

Underlying: Common Stock · 25,334 shares

Expires 2035-05-06

F3 · derivative.exercise_date: These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/6/2026.

SEC source: 0001127602-25-013780 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,985

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/6/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 442 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-013527 · form4.xml · nonDerivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,066

F1 · balance_after: These shares include 442 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-013527 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,806

SEC source: 0001127602-25-013280 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,586

F1 · balance_after: These shares include 675 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-010054 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,386

F1 · balance_after: These shares include 868 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-008422 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,271

F1 · balance_after: These shares include 773 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-25-004776 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,186

F1 · price: The price reported is an average price. The prices ranged from $294.6101 to $294.885 per share. Full information regarding the number of shares purchased at each separate price within the range set forth is available upon request by the SEC staff, the issuer or a security holder of the issuer.

F2 · balance_after: These shares include 773 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-014852 · form4.xml · derivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,860

Underlying: Common Stock · 22,930 shares

Expires 2034-05-07

F4 · derivative.exercise_date: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.

SEC source: 0001127602-24-014852 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,674

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,419 RSUs which will vest on 4/30/2025; 2,902 which will vest in installments of 1,429 on 5/2/2025, and 1,473 on 5/2/2026; 4,237 RSUs which will vest in two installments of 1,398 each on 5/2/2025 and 5/2/2026, and one installment of 1,441 on 5/2/2027; and 3,529 RSUs which will vest in installments of 1,164 on 5/7/2026, 1,165 on 5/7/2027, and 1,200 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 490 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-014506 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,145

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,419 RSUs which will vest on 4/30/2025; 2,902 which will vest in installments of 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 each on 5/2/2025 and 5/2/2026, and one installment of 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 490 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-014191 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,810

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 1,419 RSUs which will vest on 4/30/2025; 2,902 which will vest in installments of 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 each on 5/2/2025 and 5/2/2026, and one installment of 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 648 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-013811 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,568

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 1,419 RSUs which will vest on 4/30/2025; 4,330 which will vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 each on 5/2/2025 and 5/2/2026, and one installment of 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 744 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-010848 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,321

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,796 RSUs which will vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; 4,330 which will vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 each on 5/2/2025 and 5/2/2026, and one installment of 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 884 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-24-009239 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,569

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,796 RSUs which will vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; 4,330 which will vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 each on 5/2/2025 and 5/2/2026, and one installment of 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 776 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-022410 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,308

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,796 RSUs which will vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; 4,330 which will vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 on 5/2/2025 and 5/2/2026, and 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 439 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-015044 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,866

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,180 RSUs which will vest on 5/5/2024; 2,796 RSUs which will vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; 4,330 which will vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 on 5/2/2025 and 5/2/2026, and 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 439 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-014608 · form4.xml · nonDerivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,489

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 2,325 RSUs which will vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,796 RSUs which will vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; 4,330 which will vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026; and 4,237 RSUs which will vest in two installments of 1,398 on 5/2/2025 and 5/2/2026, and 1,441 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 549 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-014608 · form4.xml · derivative · entry 3

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,833

Underlying: Common Stock · 35,833 shares

Expires 2033-05-02

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.

SEC source: 0001127602-23-014608 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,348

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.

SEC source: 0001127602-23-014150 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,111

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,534 RSUs which vest in one installment on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,796 RSUs which vest in installments of 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 746 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-010914 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP, Global Commercial Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,839

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,534 RSUs which vest in one installment on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 836 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-23-009504 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,621

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,534 RSUs which vest in one installment on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 714 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-021473 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,484

F1 · kind: The transaction reported involved a gift by the reporting person of shares of the Company's common stock to a charitable donor advised fund.

F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,534 RSUs which vest in one installment of 1,534 on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 524 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013869 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,784

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,534 RSUs which vest in one installment of 1,534 on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 424 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013343 · form4.xml · nonDerivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,387

F2 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 1,534 RSUs which vest in one installment of 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 494 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013343 · form4.xml · derivative · entry 3

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,704

Underlying: Common Stock · 35,352 shares

Expires 2032-05-02

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013343 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,195

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-010186 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,865

F1 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 3,023 RSUs which vest in installments of 1,489 on 5/3/2022 and 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; and 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 632 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-008131 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,682

F1 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 3,023 RSUs which vest in installments of 1,489 on 5/3/2022 and 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; and 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 538 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-028366 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,602

F1 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 3,023 RSUs which vest in installments of 1,489 on 5/3/2022 and 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; and 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 447 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-015350 · form4.xml · nonDerivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,848

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 10,263 RSUs which vest on 11/2/2021; 3,023 RSUs which vest in installments of 1,489 on 5/3/2022 and 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; and 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,107 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-015350 · form4.xml · derivative · entry 3

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,231

Underlying: Common Stock · 36,231 shares

Expires 2031-04-30

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015350 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,630

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-011709 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,458

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 10,263 RSUs which vest on 11/2/2021; 4,511 RSUs which vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,194 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-009477 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,159

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 10,263 RSUs which vest on 11/2/2021; 4,511 RSUs which vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,045 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-028204 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,036

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 10,263 RSUs which vest on 11/2/2021; 4,511 RSUs which vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 911 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015859 · form4.xml · derivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,050

Underlying: Common Stock · 29,050 shares

Expires 2030-05-05

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015859 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,873

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 22,238 RSUs which vest in installments of 11,975 on 11/2/2020 and 10,263 on 11/2/2021; 4,511 RSUs which vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023; and 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,145 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-031964 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,024

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 22,238 RSUs which vest in installments of 11,975 on 11/2/2020 and 10,263 on 11/2/2021; and 4,511 RSUs which vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 765 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017647 · form4.xml · derivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,382

Underlying: Common Stock · 39,382 shares

Expires 2029-05-03

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.